Financial Engines Advisors L.L.C. reduced its position in Perrigo Company (NYSE:PRGO) by 26.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). Aberdeen Asset Management PLC UK now owns 3,028,619 shares of the company's stock worth $201,070,000 after buying an additional 1,195,526 shares during the period. State of Alaska Department of Revenue acquired a new position in Perrigo during the first quarter valued at $214,000. Chevy Chase Trust Holdings Inc. raised its position in shares of Perrigo by 3.2% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,130,408 shares of the company's stock worth $75,048,000 after buying an additional 390,932 shares during the period. LLC increased its position in shares of Perrigo by 56.4% in the first quarter. Nationwide Fund Advisors now owns 54,999 shares of the company's stock valued at $3,651,000 after buying an additional 1,214 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Perrigo by 4.5% in the first quarter. Legal & General Grp Inc Public Limited Co owns 0.05% invested in Perrigo Company plc Ordinary Shares (NYSE:PRGO) for 594,236 shares. Institutional investors maintain the ownership of 80.50% shares and 0.10% shares have in possession of insiders investors. Blackrock Invest Ltd Liability Com reported 0.05% of its portfolio in Perrigo Company plc Ordinary Shares (NYSE:PRGO).
Company chares are trading at $66.57 a tad under the 50 day moving average of $74.16 and which is just under the 200 day moving average of $73.30.
Perrigo Company plc (NYSE:PRGO) has made a 20.67% comeback from a 12-month low price of $63.68.
08/11/2016 - Perrigo Company had its "market perform" rating reiterated by analysts at Leerink Swann.
Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, August 10th. The dividend payment was $0.160 per share for the quarter which is $0.64 annualized. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.19 billion.
Adjusted net income was $175 million or $1.22 per share, compared to $185 million or $1.29 per share in the same period previous year. During the same quarter a year ago, the business posted $1.93 EPS. Additionally the company announced a dividend for shareholders paid on Tuesday June 13th, 2017. Investors of record on Friday, August 25th will be given a dividend of $0.16 per share. The ex-dividend date was Wednesday the 24th of May 2017. The dividend yield was $0.95. Perrigo's payout ratio is -3.51%.
WARNING: This article was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark and copyright laws.
PRGO has been the topic of several recent analyst reports. Deutsche Bank maintained Perrigo Company plc Ordinary Shares (NYSE:PRGO) on Monday, July 17 with "Buy" rating. Canaccord Genuity maintained the shares of PRGO in report on Tuesday, May 30 with "Buy" rating.
Among 18 analysts covering Perrigo Company Plc (NYSE:PRGO), 6 have Buy rating, 2 Sell and 10 Hold. Equity analyst Argus Research both downgraded the stock and lowered the price target on June 20 changing the price target from $160.00 to $97.00 and changing the rating from "Buy" to "Hold".
The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. The original version of this story can be read at https://www.thestockobserver.com/2017/08/11/wealth-enhancement-advisory-services-llc-takes-position-in-perrigo-company-nyseprgo-updated.html.
Perrigo Company plc (PRGO) holds floating shares of 142.68 million and 145.27 million outstanding shares.
It offers OTC products in various categories, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic products, natural health and vitamins, personal care and derma-therapeutics, lifestyle, and anti-parasite; consumer healthcare products; and vitamins, minerals, and supplements.